Neutrophil to Lymphocyte ratio is significantly reduced after Sodium glucose cotransporter-2 inhibitor treatment in patients with type 2 diabetes mellitus

Authors

  • Ozge Kurtkulagi Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey

DOI:

https://doi.org/10.22141/2224-0721.18.2.2022.1151

Keywords:

type 2 diabetes mellitus, inflammation, neutrophil to lymphocyte ratio, sodium glucose cotranspor­ter-2 inhibitor, fasting glucose, HbA1c

Abstract

Background. Sodium glucose cotransporter-2 inhibitors (SGLT2i) are novel therapeutic agents that became available in the treatment of type 2 diabetes mellitus (T2DM). This group of antidiabetic agents are associated with reduced glycated hemoglobin (HbA1c), fasting glucose, body weight and body mass index (BMI) in diabetic patients. All those beneficial effects may also be associated with a reduction in inflammatory burden. The purpose of the study is to compare neutrophil to lymphocyte ratio (NLR), a novel inflammatory marker derived from hemogram, before and 6 months after SGLT2i treatment in diabetic subjects. We also aimed to compare fasting glucose, HbA1c and other metabolic parameters as well as anthropometric measures (weight, BMI) before and 6 month after initiation of SGLT2i therapy. Materials and methods. The subjects with type T2DM that show up in internal medi­cine outpatient clinics of Abant Izzet Baysal University Hospital between January 2021 and December 2021 were enrolled to the study. Pretreatment and posttreatment NLR and other parameters were compared. We also obtained pretreatment and posttreatment laboratory data including urea, creatinine, fasting glucose, HbA1c, glomerular filtration rate, aspartate and alanine transaminases, plasma sodium and potassium. Results. Fasting glucose was reduced from 195 ± 72 mg/dl in pretreatment period to 146 ± 53 mg/dl in posttreatment period (p < 0.001). HbA1c was reduced from 9.1 ± 1.7 % in pretreatment period to 7.7 ± 1.7 % in posttreatment period (p < 0.001). The NLR before treatment was 2.6 ± 1.2 % before SGLT2i treatment and was reduced to 2.2 ± 0.6 % in 6th month of SGLT2i therapy. NLR was significantly decreased after treatment (p = 0.003). Conclusions. We suggest that NLR levels could be a marker of reduced inflammatory burden in T2DM subjects receiving SGLT2i treatment.

Downloads

Download data is not yet available.

References

Cakir L, Aktas G, Enginyurt O, et al. Mean platelet volume increases in type 2 diabetes mellitus independent of HbA1c level. Acta Medica Mediterranea. 2014;30:425-428.

Vernekar PV, Vaidya KA. Comparison of mean platelet volume in type 2 diabetics on insulin therapy and on oral hypoglycaemic agents. J Clin Diagn Res. 2013 Dec;7(12):2839-40. doi: 10.7860/JCDR/2013/7636.3771.

Kodiatte TA, Manikyam UK, Rao SB, et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians. 2012 Jan;4(1):5-9. doi: 10.4103/0974-2727.98662.

Atak B, Aktas G, Duman TT, Erkus E, Kocak MZ, Savli H. Diabetes control could through platelet-to-lymphocyte ratio in hemograms. Rev Assoc Med Bras (1992). 2019 Jan;65(1):38-42. doi: 10.1590/1806-9282.65.1.38.

Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases. Ann Lab Med. 2019 Jul;39(4):345-357. doi: 10.3343/alm.2019.39.4.345.

Bilgin S, Aktas G, Zahid Kocak M, Atak BM, Kurtkulagi O, Duman TT, Savli H. Association between novel inflammatory markers derived from hemogram indices and metabolic parameters in type 2 diabetic men. Aging Male. 2020 Dec;23(5):923-927. doi: 10.1080/13685538.2019.1632283.

Ji S, Ning X, Zhang B, Shi H, Liu Z, Zhang J. Platelet distribution width, platelet count, and plateletcrit in diabetic retinopathy: A systematic review and meta-analysis of PRISMA guidelines. Medicine (Baltimore). 2019 Jul;98(29):e16510. doi: 10.1097/MD.0000000000016510.

Bilgin S, Aktas G, Kurtkulagi O, Atak BM, Duman TT. Edmonton frail score is associated with diabetic control in elderly type 2 diabetic subjects. J Diabetes Metab Disord. 2020 May 12;19(1):511-514. doi: 10.1007/s40200-020-00542-z.

Kocak MZ, Aktas G, Duman TT, et al. Monocyte lymphocyte ratio As a predictor of Diabetic Kidney Injury in type 2 Diabetes mellitus; The MADKID Study. J Diabetes Metab Disord. 2020 Jul 29;19(2):997-1002. doi: 10.1007/s40200-020-00595-0.

Kucuk H, Tecer D, Goker B, et al. Platelet/lymphocyte ratio and mean platelet volume in patients with granulomatosis with polyangiitis. Adv Rheumatol. 2019 Dec 31;60(1):4. doi: 10.1186/s42358-019-0110-8.

Bilgin S, Kurtkulagi O, Atak Tel BM, et al. Does C-reactive protein to serum Albumin Ratio correlate with diabEtic nephropathy in patients with Type 2 dIabetes MEllitus? The CARE TIME study. Prim Care Diabetes. 2021 Dec;15(6):1071-1074. doi: 10.1016/j.pcd.2021.08.015.

Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020 Oct 16;295(42):14379-14390. doi: 10.1074/jbc.REV120.008387.

Leandro A, Queiroz M, Azul L, Seiça R, Sena CM. Omentin: A novel therapeutic approach for the treatment of endothelial dysfunction in type 2 diabetes. Free Radic Biol Med. 2021 Jan;162:233-242. doi: 10.1016/j.freeradbiomed.2020.10.021.

Tutunchi H, Ostadrahimi A, Hosseinzadeh-Attar MJ, Miryan M, Mobasseri M, Ebrahimi-Mameghani M. A systematic review of the association of neuregulin 4, a brown fat-enriched secreted factor, with obesity and related metabolic disturbances. Obes Rev. 2020 Feb;21(2):e12952. doi: 10.1111/obr.12952.

Kocak MZ, Aktas G, Atak BM, et al. Is Neuregulin-4 a predictive marker of microvascular complications in type 2 diabetes mellitus? Eur J Clin Invest. 2020 Mar;50(3):e13206. doi: 10.1111/eci.13206.

López-Yoldi M, Moreno-Aliaga MJ, Bustos M. Cardiotrophin-1: A multifaceted cytokine. Cytokine Growth Factor Rev. 2015 Oct;26(5):523-32. doi: 10.1016/j.cytogfr.2015.07.009.

Aktas G, Kocak MZ, Bilgin S, Atak BM, Duman TT, Kurtkulagi O. Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2020 Dec;23(5):1098-1102. doi: 10.1080/13685538.2019.1678126.

Kocak MZ, Aktas G, Erkus E, Sincer I, Atak B, Duman T. Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus. Rev Assoc Med Bras (1992). 2019 Jan;65(1):9-15. doi: 10.1590/1806-9282.65.1.9.

Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014 Oct;35(7):391-404. doi: 10.1002/bdd.1909.

Ouchi M, Oba K, Kaku K, et al. Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. Diabetes Obes Metab. 2018 Apr;20(4):1061-1065. doi: 10.1111/dom.13170.

Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539-45. doi: 10.1111/j.1463-1326.2012.01558.x.

Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract. 2018 Aug 22;4(5):477-482. doi: 10.1002/osp4.294.

Downloads

Published

2022-04-22

How to Cite

Kurtkulagi, O. (2022). Neutrophil to Lymphocyte ratio is significantly reduced after Sodium glucose cotransporter-2 inhibitor treatment in patients with type 2 diabetes mellitus. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 18(2), 86–89. https://doi.org/10.22141/2224-0721.18.2.2022.1151

Issue

Section

Original Researches

Most read articles by the same author(s)